Abstract

Attempts of establishing vaccines against cancers are in process of becoming authentic in future due to its successful clinical trials. But, there are problems in assessing the prognosis of the diseases due to the weakness and specificity of tumor associated antigens in stimulating an effective immune response. A surplus combination of immunotherapeutic cancer strategies and appropriate checkpoint inhibitors, becomes a promising area for successful cancer disease control. This article summarizes the understanding of tumor antigens (specific or associated) in head and neck squamous cell carcinoma, which allow some space with a positive and hopeful view of the future.

This work is licensed under a Creative Commons Attribution 4.0 License.